BRPI0413533A - derivados de malonamida que bloqueiam a atividade de gama-secretase - Google Patents
derivados de malonamida que bloqueiam a atividade de gama-secretaseInfo
- Publication number
- BRPI0413533A BRPI0413533A BRPI0413533-4A BRPI0413533A BRPI0413533A BR PI0413533 A BRPI0413533 A BR PI0413533A BR PI0413533 A BRPI0413533 A BR PI0413533A BR PI0413533 A BRPI0413533 A BR PI0413533A
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- halogen
- hydrogen
- cycloalkyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
"DERIVADOS DE MALONAMIDA QUE BLOQUEIAM A ATIVIDADE DE GAMA-SECRETASE". A invenção refere-s a derivados de malonamida da fórmula (I), em que: R¬ 1¬ é um dos seguintes grupos R¬ 2¬ é alquila inferior, alquinila inferior, -(CH~ 2~)~ n~-O-alquila inferior,(CH~ 2~)~ n~-S-alquila inferior, -(CH~ 2~), -CN, -(CR<39>R')~ n~-CF~ 3~, -(CR<39>R')~ n~-CHF~ 2~, (CR<39>R')~ n~-CH~ 2~F, -(CH~ 2~)~ n~-C(O)O-alquila inferior, -(CH~ 2~)~ n~-halogênio, ou é (CH~ 2~)~--cicloalquila, opcionalmente substituída por um ou mais substituintes, selecionados do grupo que consiste em fenila, halogênio ou CF~ 3~; R<39>,R' são independentemente de n e entre si hidrogênio, alquila inferior, aicóxi Inferior, halogênio ou hidróxi; R¬ 3¬, R¬ 4¬ São independentemente entre si hidrogênio, alquila inferior, alcóxi inferior, fenila ou halogênio; R¬ 5¬ é hidrogênio, alquila inferior, -(CH~ 2~)~ n~-CF~ 3~ OU -(CH~ 2~)~ n~-Cicloalquila; R¬ 6¬ é hidrogênio ou halogênio; R¬ 7¬ é hidrogênio ou alquila inferior: R¬ 8¬ é hidrogênio, alquila inferior, alquinila inferior, -(CH~ 2~)~ n~-CF~ 3~, -(CH~ 2~)~ n~-Cicloalquila ou -(CH~ 2~)~ n~-fenila, opcionalmente substituída por halogênio; R¬ 9¬ é hidrogênío, alquila inferior, -C(O)H, -C(O)-alquila inferior, -C(O)-CF~ 3~, -C(O)-CH~ 2~F, -C(O)-CHF~ 2~, -C(O)-cicloalquila, -C(O)(CH~ 2~)~ n~-O-alquila inferior, -C(O)O-(CH~ 2~)~ n~-CiCloalquila, -C(O)-fenila, opcionalmente substituída por um ou mais substituintes selecionados do grupo que consiste em halogênio ou -C(O)O alquila inferior, ou é -S(0)~ 2~-alquila inferior, S(0)~ 2~-CF~ 3~, -(CH~ 2~)~ n~-cicloalquila ou é -(CH~ 2~)~ n~-fenila, opcionalmente substituída por halogênio; n é 0, 1, 2, 3 ou 4; e a sais de adição de ácido farmaceuticamente adequados, racematos, enantiómeros oticamente puros ou sua mistura diatereomética. Estes compostos podem ser usados para o tratamento de doença de Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03019683 | 2003-09-09 | ||
| PCT/EP2004/009700 WO2005023772A1 (en) | 2003-09-09 | 2004-08-31 | Malonamide derivatives blocking the activity of gama-secretase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413533A true BRPI0413533A (pt) | 2006-10-10 |
Family
ID=34224068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413533-4A BRPI0413533A (pt) | 2003-09-09 | 2004-08-31 | derivados de malonamida que bloqueiam a atividade de gama-secretase |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7160875B2 (pt) |
| EP (1) | EP1711470B1 (pt) |
| JP (2) | JP4571639B2 (pt) |
| KR (3) | KR20070087233A (pt) |
| CN (1) | CN100593539C (pt) |
| AR (1) | AR045609A1 (pt) |
| AT (1) | ATE428698T1 (pt) |
| AU (1) | AU2004270361B2 (pt) |
| BR (1) | BRPI0413533A (pt) |
| CA (1) | CA2537440C (pt) |
| CO (1) | CO5660268A2 (pt) |
| CR (1) | CR8264A (pt) |
| CY (1) | CY1109225T1 (pt) |
| DE (1) | DE602004020680D1 (pt) |
| DK (1) | DK1711470T3 (pt) |
| EA (1) | EA009940B1 (pt) |
| EC (1) | ECSP066414A (pt) |
| ES (1) | ES2322652T3 (pt) |
| HK (1) | HK1099014A1 (pt) |
| HR (1) | HRP20090266T1 (pt) |
| IL (1) | IL173905A (pt) |
| MA (1) | MA28034A1 (pt) |
| MX (1) | MXPA06002562A (pt) |
| MY (1) | MY141308A (pt) |
| NO (1) | NO20061047L (pt) |
| NZ (1) | NZ545538A (pt) |
| PL (1) | PL1711470T3 (pt) |
| PT (1) | PT1711470E (pt) |
| RS (1) | RS20060146A (pt) |
| SI (1) | SI1711470T1 (pt) |
| TN (1) | TNSN06077A1 (pt) |
| TW (1) | TW200519092A (pt) |
| UA (1) | UA83501C2 (pt) |
| WO (1) | WO2005023772A1 (pt) |
| ZA (1) | ZA200601989B (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2311795T3 (es) * | 2003-02-04 | 2009-02-16 | F. Hoffmann-La Roche Ag | Derivados de malonamida como inhibidores de gamma-secretasa. |
| KR20070087233A (ko) * | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| US7166587B2 (en) * | 2003-10-06 | 2007-01-23 | Hoffmann-La Roche Inc. | Carbamic acid alkyl ester derivatives |
| US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| RU2440342C2 (ru) * | 2006-03-27 | 2012-01-20 | Ф.Хоффманн-Ля Рош Аг | МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ |
| AU2007299129A1 (en) * | 2006-09-20 | 2008-03-27 | F. Hoffmann-La Roche Ag | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| AU2008209861B2 (en) | 2007-02-02 | 2012-08-09 | F. Hoffmann-La Roche Ag | 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives |
| MX2009009384A (es) * | 2007-03-15 | 2009-09-14 | Hoffmann La Roche | Malonamidas como antagonistas de orexina. |
| US7579464B2 (en) | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
| EP2244713A1 (en) * | 2008-01-11 | 2010-11-03 | F. Hoffmann-La Roche AG | Use of a gamma-secretase inhibitor for treating cancer |
| US8741889B2 (en) | 2008-01-11 | 2014-06-03 | Hoffmann-La Roche Inc | Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor |
| US8309299B2 (en) * | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| KR101330184B1 (ko) | 2010-10-15 | 2013-11-15 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| WO2012050370A2 (ko) * | 2010-10-15 | 2012-04-19 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| US20120114638A1 (en) | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
| US20120184529A1 (en) | 2011-01-14 | 2012-07-19 | Demario Mark D | Combination therapy |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| CN104822665A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物 |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| JP2015534554A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物 |
| US9133139B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
| JP2015534553A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換１，５−ベンゾジアゼピノン化合物 |
| JP2015533811A (ja) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物 |
| EP2897938B1 (en) | 2012-09-21 | 2017-03-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| EP2897941B1 (en) | 2012-09-21 | 2016-09-07 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| JP6535822B2 (ja) * | 2015-10-30 | 2019-06-26 | インセプション ３， インコーポレイテッド | 耳の疾患および障害の処置におけるジベンゾアゼピン化合物およびその使用 |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US11161825B2 (en) * | 2017-08-15 | 2021-11-02 | Bayer Aktiengesellschaft | 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides |
| KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| WO2020261093A1 (en) | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| KR20240054320A (ko) * | 2021-08-31 | 2024-04-25 | 바스프 에스이 | 축합된 고리계를 함유하는 제초성 말론아미드 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1289966A1 (en) * | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| ES2311795T3 (es) * | 2003-02-04 | 2009-02-16 | F. Hoffmann-La Roche Ag | Derivados de malonamida como inhibidores de gamma-secretasa. |
| KR20070087233A (ko) * | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
-
2004
- 2004-08-31 KR KR1020077017458A patent/KR20070087233A/ko not_active Application Discontinuation
- 2004-08-31 MX MXPA06002562A patent/MXPA06002562A/es active IP Right Grant
- 2004-08-31 PT PT04764665T patent/PT1711470E/pt unknown
- 2004-08-31 ES ES04764665T patent/ES2322652T3/es active Active
- 2004-08-31 BR BRPI0413533-4A patent/BRPI0413533A/pt not_active Application Discontinuation
- 2004-08-31 DE DE602004020680T patent/DE602004020680D1/de active Active
- 2004-08-31 WO PCT/EP2004/009700 patent/WO2005023772A1/en active Application Filing
- 2004-08-31 EA EA200600503A patent/EA009940B1/ru not_active IP Right Cessation
- 2004-08-31 RS YUP-2006/0146A patent/RS20060146A/sr unknown
- 2004-08-31 KR KR1020077017457A patent/KR100838852B1/ko active IP Right Grant
- 2004-08-31 AU AU2004270361A patent/AU2004270361B2/en not_active Ceased
- 2004-08-31 AT AT04764665T patent/ATE428698T1/de active
- 2004-08-31 PL PL04764665T patent/PL1711470T3/pl unknown
- 2004-08-31 KR KR1020067004763A patent/KR100834177B1/ko active IP Right Grant
- 2004-08-31 UA UAA200602854A patent/UA83501C2/uk unknown
- 2004-08-31 CN CN200480032641A patent/CN100593539C/zh active Active
- 2004-08-31 SI SI200431116T patent/SI1711470T1/sl unknown
- 2004-08-31 JP JP2006525701A patent/JP4571639B2/ja active Active
- 2004-08-31 DK DK04764665T patent/DK1711470T3/da active
- 2004-08-31 NZ NZ545538A patent/NZ545538A/en not_active IP Right Cessation
- 2004-08-31 EP EP04764665A patent/EP1711470B1/en active Active
- 2004-08-31 CA CA2537440A patent/CA2537440C/en not_active Expired - Fee Related
- 2004-09-02 US US10/933,177 patent/US7160875B2/en active Active
- 2004-09-06 TW TW093126876A patent/TW200519092A/zh unknown
- 2004-09-06 MY MYPI20043603A patent/MY141308A/en unknown
- 2004-09-08 AR ARP040103214A patent/AR045609A1/es not_active Application Discontinuation
-
2006
- 2006-02-23 IL IL173905A patent/IL173905A/en active IP Right Grant
- 2006-02-23 CO CO06018272A patent/CO5660268A2/es not_active Application Discontinuation
- 2006-03-01 CR CR8264A patent/CR8264A/es not_active Application Discontinuation
- 2006-03-03 NO NO20061047A patent/NO20061047L/no not_active Application Discontinuation
- 2006-03-07 TN TNP2006000077A patent/TNSN06077A1/fr unknown
- 2006-03-07 EC EC2006006414A patent/ECSP066414A/es unknown
- 2006-03-08 ZA ZA200601989A patent/ZA200601989B/en unknown
- 2006-03-10 MA MA28867A patent/MA28034A1/fr unknown
-
2007
- 2007-05-21 HK HK07105326.7A patent/HK1099014A1/xx not_active IP Right Cessation
-
2009
- 2009-05-12 HR HR20090266T patent/HRP20090266T1/xx unknown
- 2009-07-10 CY CY20091100729T patent/CY1109225T1/el unknown
-
2010
- 2010-06-18 JP JP2010138970A patent/JP2010229153A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413533A (pt) | derivados de malonamida que bloqueiam a atividade de gama-secretase | |
| BR0213612A (pt) | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BRPI0409109A (pt) | novos compostos | |
| HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| SE0104334D0 (sv) | Therapeutic agents | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| HUP0401307A2 (hu) | 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények | |
| NO20076498L (no) | Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren | |
| BR0210384A (pt) | Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença | |
| NO20091560L (no) | Biaryleterureaforbindelser | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| MA29909B1 (fr) | Derives de pyridazine | |
| SE0302760D0 (sv) | New compounds | |
| HUP0204147A2 (hu) | [(RR,SS)-3-(2-dimetilaminoetil-1-hidroxiciklohexil)fenil]-2-hidroxibenzoátból származtatott új észterek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| BRPI0407695A (pt) | compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2 | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли | |
| EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
| AR041298A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| BRPI0415070B8 (pt) | derivados de dibenzo-azepina e benzo-diazepina substituídos úteis, seu uso e seu processo de preparação, e medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. C07D 223/18, 223/16, 243/14, 313/14; A61K 31/5513, 31/55; A61P 25/28 Ipc: C07D 223/18 (2011.01), C07D 223/16 (2011.01), C07D |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |